Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 16;11(4):e70177.
doi: 10.1002/trc2.70177. eCollection 2025 Oct-Dec.

Evaluation of self-mediated alternatives for risk testing education and return of results (eSMARTER) study: A randomized study of methods for returning APOE and pTau-217 results

Claire M Erickson  1 , Carolyn M Langlois  1 , Elisabeth McCarty Wood  2 , Rajia Mim  2 , Sarah Howe  2 , Demetrios Ofidis  2 , Brian L Egleston  3 , Kristin Harkins  4 , Emily A Largent  5 , J Scott Roberts  6 , Eric M Reiman  1 , Marisa Denkinger  7 , Nicholas J Ashton  7 , Jason Karlawish  4   5 , Angela R Bradbury  2   5 , Jessica B Langbaum  1
Affiliations

Evaluation of self-mediated alternatives for risk testing education and return of results (eSMARTER) study: A randomized study of methods for returning APOE and pTau-217 results

Claire M Erickson et al. Alzheimers Dement (N Y). .

Abstract

Introduction: Disclosing Alzheimer's disease (AD) genetic and biomarker information is becoming increasingly common but often resource-intensive, requiring a clinician to return results. As results become relevant for clinical care and more people want to learn their results, scalable approaches to disclosure are needed. Here, we describe the design of a decentralized, randomized, non-inferiority clinical trial (eSMARTER) to evaluate self-directed scalable digital methods for returning APOE and plasma pTau-217 results.

Methods: Participants (n ≈ 600) aged 60-80 years are randomized to receive their apolipoprotein E (APOE) and pTau-217 results via either a clinician-mediated telehealth videoconference (usual care) or a self-mediated eHealth platform. The primary hypothesis is that self-mediated APOE disclosure will result in non-inferior outcomes compared to clinician-mediated disclosure. The three primary outcomes are changes in anxiety, AD-related knowledge, and disease-specific distress. For the three primary analyses, we will apply non-inferiority tests to examine if self-mediated disclosure provides equivalent or improved outcomes compared to usual care. Our secondary hypothesis is that learning APOE and pTau-217 results will affect participants' mood, self-perception of disease risk, and quality of life. We hypothesize participants who learn results indicating more risk will report increased, but not clinically significant psychological distress and increased disease risk. We hypothesize there will not be changes in quality of life. We will examine change scores of the validated mood, self-perception of disease risk, and quality of life measures from pre- to post-disclosure.

Results: Data collection is ongoing. Results will allow for non-inferiority comparisons between clinician- and self-mediated disclosure of APOE results and initial characterization of the impact of learning pTau-217 results.

Discussion: The eSMARTER Study represents an important step towards meeting expected increases in demand for learning AD genetic and biomarker information. The digital platforms developed for this study will be made available to support clinicians and investigators returning genetic and/or biomarker results.

Highlights: Novel, scalable design for self-mediated disclosure of APOE and pTau-217.Non-inferiority trial examining self-mediated versus clinician-mediated disclosure.All materials, methods, data, and samples will be shared publicly.

Keywords: APOE; digital methods; non‐inferiority trial; pTau‐217; return of results; self‐disclosure.

PubMed Disclaimer

Conflict of interest statement

Jessica B. Langbaum reports receiving consulting fees from Denovo Biopharma and Premiere Inc. Emily A. Largent reports receiving consulting fees from Novartis. Eric M. Reiman is a compensated scientific advisor for Alzheon, Cognition Therapeutics, Denali Therapeutics, Enigma, Jocanta, Retromer Therapeutics, and Vaxxinity. He is a co‐founder, advisor, and shareholder in ALZPath. Jason Karlawish reports receiving consultation fees from Biogen and Darmiyan. The rest of the authors have no conflicts of interest to report. The rest of the authors have no relevant disclosures to report. Author disclosures are available in the Supporting Information.

Figures

FIGURE 1
FIGURE 1
Study design.
See this image and copyright information in PMC

References

    1. Rahman‐Filipiak A, Chin NA, Kohl H, et al. Return of research results across the Alzheimer's Disease Research Centers network. Alzheimers Dement. 2025;21(6):e70418. doi: 10.1002/alz.70418 - DOI - PMC - PubMed
    1. Largent EA, Bhardwaj T, Abera M, et al. Disclosing genetic risk of Alzheimer's disease to cognitively unimpaired older adults: findings from the Study of Knowledge and Reactions to APOE Testing (SOKRATES II). J Alzheimers Dis. 2021;84(3):1015–1028. doi: 10.3233/JAD-210675 - DOI - PMC - PubMed
    1. Largent EA, Harkins K, van Dyck CH, Hachey S, Sankar P, Karlawish J. Cognitively unimpaired adults’ reactions to disclosure of amyloid PET scan results. PLOS ONE. 2020;15(2):e0229137. doi: 10.1371/journal.pone.0229137 - DOI - PMC - PubMed
    1. Clark LR, Chin NA, Erickson CM, et al. Impact of learning amyloid PET results on test‐related distress and concern about dementia in a cognitively unimpaired observational cohort. Alzheimers Dement. 2023;19(S19):e078746. doi: 10.1002/alz.078746 - DOI
    1. Grill JD, Raman R, Ernstrom K, et al. Short‐term psychological outcomes of disclosing amyloid imaging results to research participants who do not have cognitive impairment. JAMA Neurol. 2020;77(12):1504–1513. doi: 10.1001/jamaneurol.2020.2734 - DOI - PMC - PubMed

LinkOut - more resources